# Belharra Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/belharra-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.belharratx.com
- Total disclosed funding: $130M
- Latest round: Series A (Jan 4, 2023)
- Investors on record: 2

## About

Based in California, US, and founded in 2021 by Christopher G. Parker, John Teijaro, Benjamin Cravatt, and Stuart Schreiber, Belharra Therapeutics operates as a drug discovery platform that develops novel drugs and therapies for difficult-to-treat diseases. In January 2023, Belharra Therapeutics, Inc. raised USD 130 million in Series A funding from new investors Genentech, Inc. and Versant Ventures. The firm’s partners include Scripps Research and Genentech.

The company operates a chemoproteomic-based drug discovery platform that identifies functional and actionable non-covalent, small molecule drug candidates for any binding site, on any protein, in any conformational state, and in any cell type. The platform allows screens to be run in a whole cell context, allowing the small molecule library to interact with proteins in their native conformations, including protein complexes, to create and identify therapeutics for previously difficult-to-treat conditions.

## Funding rounds

- Series A, Jan 4, 2023, $130M — Versant Ventures, Genentech, Inc.

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Genentech, Inc. — Series A